Related Experiment Videos
Prodrug/drug sensitivity gene therapy: current status
1The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 80, Houston, TX 77030, USA.
Current Oncology Reports
|December 21, 2000
Summary
Prodrug gene therapy overcomes obstacles using the bystander effect for enhanced efficiency. Clinical trials show success, paving the way for combination therapies targeting tumors.
Area of Science:
- Oncology
- Gene Therapy
- Pharmacology
Background:
- Prodrug gene therapy faces theoretical and practical challenges.
- The bystander effect enhances prodrug system efficiency by affecting nearby nontransduced cells.
- Established systems include HSVtk/GCV and CD/5-FC.
Purpose of the Study:
- To review the progress and clinical application of prodrug gene therapy.
- To highlight the role of the bystander effect in prodrug gene therapy efficacy.
- To discuss the future potential of prodrug gene therapy, including combination strategies.
Main Methods:
- Review of preclinical and clinical research on prodrug gene therapy systems.
- Analysis of specific prodrug gene therapy systems like HSVtk/GCV and CD/5-FC.
- Examination of data from ongoing and approved clinical trials.
Main Results:
- The bystander effect significantly boosts the efficiency of prodrug gene therapy.
- Multiple prodrug gene therapy systems have been developed and tested.
- Over 21 prodrug gene therapy trials are approved in the US and Europe.
- Recent studies demonstrate successful outcomes in prodrug gene therapy.
Conclusions:
- Prodrug gene therapy is a promising approach to cancer treatment.
- The bystander effect is a key mechanism for enhancing therapeutic outcomes.
- Combination therapies involving prodrug/suicide and immune-enhancing genes show future potential for tumor treatment.